The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Areas of unmet need for DLBCL: primary refractory disease and double-hit lymphoma
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses areas of unmet needs for patients with diffuse large B-cell lymphoma (DLBCL), drawing focus on patients with primary refractory disease who do not respond to standard of care treatment. In addition, Dr Phillips highlights double-hit lymphoma, an aggressive type of B-cell non-Hodgkin lymphoma characterized by translocations involving MYC, and BCL-2 or BCL-6, and are associated with a poor prognosis when treated with standard chemoimmunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
